Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study

Table 1 Chemotherapy regimens

Regimen	Drug	Dose	Schedule	Total dose
Induction regimens
CEDC^a	Cisplatin	60 mg/m²/day	Day 0	60 mg/m²
	Etoposide	100 mg/m²/day	Days 2, 5	200 mg/m²
	Doxorubicin	30 mg/m²/day	Day 2	30 mg/m²
	Cyclophosphamide	30 mg/kg/day	Days 3, 4	60 mg/kg
ICE^a	Ifosfamide	1 200 mg/m²/day	Days 0–4	6 000 mg/m²
	Carboplatin	400 mg/m²/day	Days 0, 1	800 mg/m²
	Etoposide	100 mg/m²/day	Days 0−4	500 mg/m²
First HDCT regimen
CEC	Carboplatin	650 mg/m²/day	Days −7, −6, −5	1 950 mg/m²
	Etoposide	650 mg/m²/day	Days −7, −6, −5	1 950 mg/m²
	Cyclophosphamide	1 800 mg/m²/day	Days −4, −3, −2	5 400 mg/m²
Second HDCT regimens
¹³¹I-MIBG-TM	¹³¹I-MIBG	18 or 12 mCi/kg	Days −21	12 or 18 mCi/kg
	Thiotepa	200 mg/m²/day	Days −6, −5, −4	600 mg/m²
	Melphalan	60 mg/m²/day	Days −3, −2	120 mg/m²
TM	Thiotepa	300 mg/m²/day	Days −6, −5, −4	900 mg/m²
TM	Melphalan	60 mg/m²/day	Days −3, −2	120 mg/m²

MIBG meta-iodobenzylguanidine
^aThe chemotherapy dose was reduced for patients younger than 24 months of age, i.e., kilogram-based dose for <6 months of age, 70% of dose based on body surface area for 6–11 months of age, 80% of dose for 12–17 months of age, and 90% of dose for 18–23 months of age

ISSN: 1756-8722